Long-term smallcap play, Clarity Pharmaceuticals (ASX:CU6)
Clarity is a clinical-stage radiopharmaceutical company developing targeted theranostics — drugs that combine diagnostic imaging and therapy — using copper isotopes (Cu-64 and Cu-67).
SAR-bisPSMA: A dual-function radiopharmaceutical targeting PSMA for both imaging (with 64Cu) and therapy (with 67Cu) in prostate cancer. Est. market entry 2026-2027
SAR-Bombesin: Targets the gastrin-releasing peptide receptor (GRPR) for imaging and treatment of GRPR-positive cancers, including prostate and breast cancers. Est. market entry 2027-2028
SARTATE: Designed for diagnosing and treating neuroblastoma and neuroendocrine tumors using copper isotopes. Est. market entry 2028+
SAR-trastuzumab: A preclinical radioimmunotherapy combining trastuzumab with Clarity’s SAR Technology to target HER2-positive breast cancer. Est. market entry 2030+
SAR-bisPSMA: A dual-function radiopharmaceutical targeting PSMA for both imaging (with 64Cu) and therapy (with 67Cu) in prostate cancer. Est. market entry 2026-2027
SAR-Bombesin: Targets the gastrin-releasing peptide receptor (GRPR) for imaging and treatment of GRPR-positive cancers, including prostate and breast cancers. Est. market entry 2027-2028
SARTATE: Designed for diagnosing and treating neuroblastoma and neuroendocrine tumors using copper isotopes. Est. market entry 2028+
SAR-trastuzumab: A preclinical radioimmunotherapy combining trastuzumab with Clarity’s SAR Technology to target HER2-positive breast cancer. Est. market entry 2030+
Dagangan aktif
Its outside of the range for now. Not expexting this to last forever but won't be upset if it does. Looking forward to seeing the MA's cross.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.